Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Double-Blind, Double-Dummy, Parallel-Group, Randomized, Positive Control Study Using fMRI to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users

Next Previous
Trial Profile

A Phase 1 Double-Blind, Double-Dummy, Parallel-Group, Randomized, Positive Control Study Using fMRI to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 12 Jul 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oxycodegol (Primary) ; Oxycodone
  • Indications Back pain; Musculoskeletal pain; Pain
  • Focus Pharmacodynamics
  • Sponsors Nektar Therapeutics

Most Recent Events

  • 14 Feb 2020 Status changed from recruiting to discontinued.
  • 29 Oct 2019 Planned End Date changed from 26 Apr 2019 to 30 Mar 2020.
  • 29 Oct 2019 Planned primary completion date changed from 26 Apr 2019 to 30 Mar 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top